The Trump administration on Monday sang powerful new weight loss drugs including Vagovi and Zepbounds as their push to reduce the prices of their prescription drugs.

President Donald Trump’s executive order demands that drug manufacturers cut prices on their products in the coming months, which they charge in other developed countries, or with export restrictions to tariffs, face new rules and enforcement operations.

At the signature ceremony, Trump described a conversation with a business friend, who said how expensive weighing remedies are there in the United States.

Trump said, “I am in London, and I only paid for this shameful fat medicine,” Trump said to the person. “I have just paid $ 88 and in New York I paid $ 1,300. What is going on in hell? … This is the same box built by the same company in the same plant.” “He did not name the medicine.

The US list prices have a list of more than $ 1,000 per month in the Zipbound of Wet-Loss Drugs Wagovi from Novo Nordisk, and Eli Lily. For some patients, most of that cost is covered by health insurance. For those people without coverage, both Novo and Lily recently began selling their drugs directly to American consumers at a cash price of $ 499 per month.

But 40% of Americans are estimated to be obese, American politicians and healthcare experts have urged both companies to make treatment more cheap.

A White House official told reporters on Monday that Trump’s executive order would “focus a special focus on drugs where the greatest inequalities and biggest expenses.”

The official said, “It would be appropriate to expect GLP -1S, given that they kill both of those categories, a focus,” vejovi and zipbound as well as the respective diabetes drugs referring to the class of drugs for weight loss of ozmpic and mounzaro.

“There will be a hope that those prices should be reduced, and then if they do not, we will look at our various policy livers that can be used to reduce prices.”

Lily said on Monday that it agrees that the cost of success drugs should be shared more fairly in developed countries. But the drug manufacturer at Indianapolis said that this could only happen if the mediator within the US healthcare system, such as the pharmacy profit manager, takes a small share of the sales transactions.

Danish drug manufacturer Novo Nordisk stated that it agrees that “Americans need more access to cheap medicine, and we will continue to join with policy makers.”

Countries that are mainly provided by the government to health insurance, often interact with pharmaceutical companies at low prices. For example, in Japan, the monthly value for 10 mg zipbound injection pens is $ 61.68.

Trade is closed that some medicines are not covered under the government -run schemes. In the UK, access to new obesity drugs within National Health Services is very limited, while Germany’s health plan does not cover drugs for weight loss.

“These drug pricing issues resonate to many people on GLP-1s,” said Benedic Empolito, a senior partner of the study of economic policy at the American Enterprise Institute.

Many American patients also came to rely on very cheap copy versions of GLP-1s created by compounding to pharmacies, a practice that will soon end under a crack by the Food and Drug Administration, now the drugs called brand are no longer in shortage.